{"id":"https://openalex.org/W4395074694","doi":"https://doi.org/10.1016/j.esmoop.2024.102990","title":"Antibody\u2013drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?","display_name":"Antibody\u2013drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?","publication_year":2024,"publication_date":"2024-04-24","ids":{"openalex":"https://openalex.org/W4395074694","doi":"https://doi.org/10.1016/j.esmoop.2024.102990","pmid":"https://pubmed.ncbi.nlm.nih.gov/38796286","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11145748"},"language":"en","primary_location":{"id":"doi:10.1016/j.esmoop.2024.102990","doi":"https://doi.org/10.1016/j.esmoop.2024.102990","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.102990","pdf_url":"http://www.esmoopen.com/article/S2059702924007580/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"volume":null,"type":"editorial","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://www.esmoopen.com/article/S2059702924007580/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013516632","display_name":"Sarah LeNoir Sammons","orcid":"https://orcid.org/0000-0003-2589-9422","observed_orcids":["https://orcid.org/0000-0003-2589-9422"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Sammons","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA","Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston","Harvard Medical School, Boston, USA","Medical Oncology, Dana-Farber Cancer Institute, Boston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579","https://openalex.org/I4210161994"]},{"raw_affiliation_string":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston","institution_ids":["https://openalex.org/I4210161994"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"N.U. Lin","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA. Electronic address: Nancy_Lin@dfci.harvard.edu","Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston","Harvard Medical School, Boston, USA","Medical Oncology, Dana-Farber Cancer Institute, Boston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA. Electronic address: Nancy_Lin@dfci.harvard.edu","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579","https://openalex.org/I4210161994"]},{"raw_affiliation_string":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston","institution_ids":["https://openalex.org/I4210161994"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5022319770"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579","https://openalex.org/I4210161994"],"apc_list":{"value":3730,"currency":"USD","value_usd":3730},"apc_paid":{"value":3730,"currency":"USD","value_usd":3730},"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"9","issue":"5","first_page":"102990","last_page":"102990"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.48170000314712524,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.48170000314712524,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.4629000127315521,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.013799999840557575,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9409999847412109},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.9850000143051147},{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.9980000257492065},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.9959999918937683},{"id":"https://openalex.org/keywords/destiny-breast03","display_name":"DESTINY-Breast03","score":0.8930000066757202},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.7829999923706055}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6729125380516052},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5911878943443298},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.526513934135437},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.5126397013664246},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.5118007063865662},{"id":"https://openalex.org/C2994463257","wikidata":"https://www.wikidata.org/wiki/Q233309","display_name":"Brain cancer","level":3,"score":0.49545347690582275},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4906112253665924},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4685932695865631},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4568335711956024},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32534658908843994},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.29599207639694214},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.20270338654518127},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.19587647914886475},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.esmoop.2024.102990","doi":"https://doi.org/10.1016/j.esmoop.2024.102990","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.102990","pdf_url":"http://www.esmoopen.com/article/S2059702924007580/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11145748","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11145748","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11145748/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"Text"},{"id":"pmid:38796286","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38796286","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO open","raw_type":"Editorial"}],"best_oa_location":{"id":"doi:10.1016/j.esmoop.2024.102990","doi":"https://doi.org/10.1016/j.esmoop.2024.102990","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.102990","pdf_url":"http://www.esmoopen.com/article/S2059702924007580/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320318946","display_name":"Relay Therapeutics","ror":"https://ror.org/02bkgy413"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320321625","display_name":"Daiichi-Sankyo","ror":"https://ror.org/027y26122"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4395074694.pdf","grobid_xml":"https://content.openalex.org/works/W4395074694.grobid-xml"},"referenced_works_count":16,"referenced_works":["https://openalex.org/W2119997685","https://openalex.org/W2129749518","https://openalex.org/W2776537462","https://openalex.org/W2921590809","https://openalex.org/W3030461309","https://openalex.org/W3165169142","https://openalex.org/W3167499853","https://openalex.org/W4220678342","https://openalex.org/W4281398334","https://openalex.org/W4281619692","https://openalex.org/W4290673816","https://openalex.org/W4310566600","https://openalex.org/W4311116389","https://openalex.org/W4378193723","https://openalex.org/W4387825835","https://openalex.org/W4395084916"],"related_works":["https://openalex.org/W4368282444","https://openalex.org/W4282922771","https://openalex.org/W7172299456","https://openalex.org/W3167499853","https://openalex.org/W4309016791","https://openalex.org/W4220678342","https://openalex.org/W3202058930","https://openalex.org/W4400315718","https://openalex.org/W4294958620","https://openalex.org/W4395084916"],"abstract_inverted_index":{"In":[0],"this":[1],"issue":[2],"of":[3,13,24],"ESMO":[4],"Open,":[5],"Hurvitz":[6],"and":[7,38],"colleagues1":[8],"report":[9],"an":[10],"exploratory":[11],"analysis":[12],"trastuzumab":[14,18],"deruxtecan":[15],"(T-DXd)":[16],"versus":[17,59],"emtansine":[19],"(T-DM1)":[20],"in":[21,71],"the":[22,44,50],"subgroup":[23],"82":[25],"patients":[26],"with":[27,57,61],"human":[28],"epidermal":[29],"growth":[30],"factor":[31],"receptor":[32],"2":[33],"(HER2)-positive":[34],"metastatic":[35],"breast":[36,73],"cancer":[37,74],"baseline":[39],"brain":[40],"metastases":[41],"(BrMs)":[42],"from":[43],"landmark":[45],"DESTINY-Breast03":[46],"clinical":[47],"trial.":[48],"Impressively,":[49],"intracranial":[51],"response":[52],"rate":[53],"(i-ORR)":[54],"was":[55],"65.7%":[56],"T-DXd":[58],"34.3%":[60],"T-DM1":[62],"confirming":[63],"antibody\u2013drug":[64],"conjugates":[65],"(ADCs)":[66],"as":[67],"a":[68],"promising":[69],"strategy":[70],"treating":[72],"BrMs.":[75]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-04-25T00:00:00"}